Lotte Biologics Signs Antibody CDMO Agreement with US Oncology Biotech Company
On April 1, Lotte Biologics announced that it has signed a Contract Development and Manufacturing Organization (CDMO) agreement with a US-based biotechnology company specializing in oncology for the production and process development of antibody drug substances.
Under this agreement, Lotte Biologics will be responsible for producing antibody samples required for global late-phase clinical trials and optimizing large-scale processes. The company will support these efforts through its Syracuse Bio Campus in New York, USA.
The company explained that this agreement is significant as it is a project that considers not only clinical sample production but also subsequent clinical and commercialization stages. For antibody therapeutics, establishing the initial process is regarded as a key factor for successful commercialization. Lotte Biologics plans to reliably support clinical and commercialization preparation for the candidate material through its proven manufacturing capabilities and large-scale production facilities.
Lotte Biologics is utilizing the Syracuse Bio Campus as a hub for expanding collaborations with client companies. The company plans to further strengthen its customer-tailored integrated CDMO services and supply chain management (SCM) capabilities based on integrated quality operations across both campuses, by linking them with the Songdo Bio Campus, which is scheduled for completion this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from Lotte Biologics stated, "This order serves as a stepping stone toward securing large-scale contracts with biotechnology companies specializing in oncology," and added, "We will make every effort to ensure that this leads not only to commercialization but also to additional contract wins."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.